Tag Archives: Carcinoma

Latest Carcinoma News

September 11, 2012     No comments

Pfizer cancer pill gets EU OK as 2nd treatment
The European Commission approved the use of Inlyta in adult patients with renal cell carcinoma who have already been treated unsuccessfully with certain other kidney cancer drugs. Inlyta, known chemically as axitinib, is a pill that's part of a …
Read more on Crain’s New York Business

Vismodegib Effective Against Skin Cancer in Patients With Basal-Cell Nevus …
The oral hedgehog pathway inhibitor vismodegib (Erivedge) is effective for both the prevention and treatment of basal-cell carcinoma in patients with the rare disorder known as basal-cell nevus syndrome, according to a recent study. “Our results …
Read more on OncLive

Read More

Latest Carcinoma News

September 10, 2012     No comments

Marlborough charter school students winners in no-tanning contest
Indoor tanners are also 2.5 times more likely to develop squamous cell carcinoma, and 1.5 times more likely to develop basal cell carcinoma,” said Alani, a member of the Melanoma Foundation of New England's Medical Advisory Board. "We congratulate …
Read more on Wicked Local

Meda granted marketing authorization for Zyclara in EU – Quick Facts
The company said Actinic keratosis, or AK, early skin carcinoma in situ is an under-diagnosed and under-treated disease and the number of affected patients is increasing. Meda claimed Zyclara is to date the first clinically proven treatment option …
Read more on RTT News

Read More

Cutaneous HPV linked to squamous cell carcinoma

August 13, 2012     No comments

Cutaneous HPV linked to squamous cell carcinoma
Squamous cell carcinoma (SCC) was positively associated with antibodies to several types of cutaneous human papillomavirus (HPV) in a case control study. Cutaneous HPV infection, which differs from the mucosal HPV infection associated with cervical …
Read more on Oncology Nurse Advisor

Paper highlights clinical and immunological activity of immatics' IMA901 in …
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine …
Read more on News-Medical.net

Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In …
Pfizer Inc. announced today that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL® (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-a-2a) in the first-line treatment of patients with …
Read more on eYugoslavia.com

MultiCell announces new cancer therapeutics preclinical results
The results will further aid mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as therapeutic agents to treat hepatocellular carcinoma and other cancers. Primary liver cancer results from Hepatitis B …
Read more on Pharmaceutical Business Review

Read More

Latest Carcinoma News

August 13, 2012     No comments

Liver Cancer News: Beta-Carotene May Prevent Hepatocellular Carcinoma
Monday July 23, 2012 (foodconsumer.org) — Taking beta-carotene supplements or eating foods rich in this nutrient may help prevent hepatocellular carcinoma, a major type of liver cancer, according to a study published July 18, 2012 in Molecules. The …
Read more on Food Consumer

Bayer: Addition Of Tarceva To Nexavar Failed To Meet Goals In Late Stage Study
PK), as well as Onyx Pharmaceuticals, Inc. (ONXX:Quote), and Japan's Astellas Pharma Inc. on Monday said the addition of cancer drug Tarceva to standard therapy Nexavar in a Phase III trial in patients with Hepatocellular carcinoma did not improve …
Read more on RTT News

Risk of Residual Disease Up in Triple Negative Breast Cancer
10 (HealthDay News) — Women with triple negative (TN) breast cancer have a significantly increased risk of residual carcinoma after lumpectomy, according to a study published in the Aug. 15 issue of Cancer. Shirin Sioshansi, M.D., from the UMass …
Read more on Doctors Lounge

Read More

Prior Basal Cell Carcinoma Is Main Predictor of Future BCC

August 12, 2012     No comments

Prior Basal Cell Carcinoma Is Main Predictor of Future BCC
MONDAY, July 30 (HealthDay News) — Prior basal cell carcinoma (BCC) is the greatest predictor of future incidence of BCC, according to a study published online July 19 in the Journal of Investigative Dermatology. In a prospective six-year trial, Robert K.
Read more on Doctors Lounge

Skin cancer treatments without surgery
There are many types of skin cancer, the most common being basal cell carcinoma (80 percent), squamous cell carcinoma (16 percent) and malignant melanoma (4 percent). This is not a complete least as there are a number of other unusual types we see.
Read more on Tampa Bay Newspapers

Read More

With topics like Headaches, HIV, IBS, Hepatitis, Apnea, Alcoholism and Heptocellular Carcinoma, Audio-Digest Foundation releases free written summaries via Amazon Kindle.

August 07, 2012     No comments


Glendale, CA (PRWEB) July 18, 2012

For Wednesday, July 17, 2012, Audio-Digest Foundation will be giving away the following Written Summaries on Amazon Kindle:

Anesthesiology CME: Issues in Eye Care

Emergency Medicine CME: Outdoor Hazards

Family Medicine CME: Concepts in Headache Management

Family Medicine CME: Issues in HIV Medicine

Gastroenterology CME: Inflammatory Bowel Disease: Part 1

General Surgery CME: Acute Care Surgery: Part 2

Internal Medicine CME: Cardiology for the Internist/Hospitalist

Internal Medicine CME: Antimicrobial Stewardship in Infectious Disease

Neurology CME: Neurology Potpourri

Obstetrics/Gynecology CME: Issues in Hepatitis

Oncology CME: Hepatocellular Carcinoma

Ophthalmology CME: Current and Future Trends

Orthopaedics CME: Scoliosis/Club Foot/Rheumatoid Arthritis

Otolaryngology CME: Sleep Apnea: Pathophysiology, Clinical Presentation, and Treatment

Pediatrics CME: Psychiatric Issues

Psychiatry CME: Update on Alcoholism

Urology CME: Managing Penile Problems/Treatment of BPH

Audio-Digest Foundation, the largest independent publisher of Continuing Medical Education in the world, publishes programs in anesthesiology, emergency medicine, family practice, gastroenterology, general surgery, internal medicine, neurology, obstetrics/gynecology, oncology, ophthalmology, orthopaedics, otolaryngology, pediatrics, psychology, and urology programs via Amazon Kindle.

For 60 years, Audio-Digest Foundation has been serving the global medical community of doctors, nurses, physician assistants, and other medical professionals with a comprehensive program of the most cutting-edge, independent, and unbiased continuing medical education (CME).

Long a technical innovator, Audio-Digest was the first to produce audio medical education programs and the first to produce in-car medical education. Currently, its subscription and annual products are available on CD and MP3, as well as iPhone, iPad, and Android apps.

According to Paul Angles, Internet Marketing Director for Audio-Digest Foundation, “Releasing our written summaries on Kindle allows our subscribers to take advantage of the portability and convenience of the Kindle, and lets non-subscribers and even patients learn more about specific conditions and treatments.”

Because of its massive library of titles, Audio-Digest Foundation plans to release written summaries of its CME titles daily through August.







Read More

Global Renal Cell Carcinoma (RCC) Drugs Market to Reach $3.03 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

May 27, 2012     No comments

San Jose, CA (PRWEB) June 06, 2011

Global incidence of kidney cancer is on the rise. Despite being a smaller segment in the overall oncology market compared to other cancers, kidney cancer emerged as a key area of research and development, and attracted significant investments from various pharmaceutical and biotechnology majors. Though just five to six drugs are presently approved, there are many others in the pipeline, including targeted therapies that are expected to make kidney cancer market an active ground for competition in future. New and emerging therapies are counteracting the drawbacks associated with traditional treatment, such as Interleukin-2 and Interferon-alpha that are characterized by low response rate and poor tolerability. Targeted therapies, in particular, possess significant opportunities in capitalizing on these unmet medical needs.

Among the various types of kidney cancers, Renal Cell Carcinoma (RCC) is the predominant type of kidney cancer, accounting for about 90% of all kidney cancers. Key factors driving market growth include increase in treatment rate and diagnosed incidence, introduction of new emerging therapies, increased use of combination therapies, and introduction of more efficient and effective targeted therapies. Another potential growth driver for the RCC market would be the increased use of GSK?s recently 2009 FDA-approved multi-kinase inhibitor, Votrient. In addition, newer therapies, such as Wilex?s Rencarex (Girentuximab), which is presently in Phase III trials, and established targeted agents, such as Sutent, Avastin, and Nexavar are also being evaluated in adjuvant setting. Patients with localized as well as locally advanced cancer represent the target patient population for treatment with adjuvant therapy and targeted therapies.

With the highest number of kidney cancer cases, the United States and Europe leads the global market for RCC drugs, as stated by the new market research report on Kidney Cancer Drugs. Accounting for a major share of the market, the US constitutes the world?s largest market for RCC drugs. Growth is expected to mainly emanate from the Asia-Pacific market, which is forecast to register a CAGR of more than 14% during the analysis period. In terms of therapeutic class, Multikinase Inhibitors dominate the RCC drugs market globally. Of all the therapeutic options available for advanced RCC, Pfizer?s Sutent has transpired to show significant potential for the treatment of the disease, and demonstrated superior efficacy compared to the traditional standard treatment of Interleukin-2 and Interferon-alpha. Sutent is presently the standard of care for treatment of na?ve patients with advanced RCC. Other RCC drugs include Bayer/Onyx?s Nexavar, Pfizer?s Torisel, Novartis? Afinitor, Roche?s Avastin, and GlaxoSmithKline?s Votrient/Patorma.

Major players profiled in the report include AVEO Pharmaceuticals, AstraZeneca Plc., Bayer Schering Pharma AG, Bristol-Myers Squibb Co., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Merck-Serono, Novartis AG, Pfizer Inc., WILEX AG, among others.

The research report titled ?Kidney Cancer Drugs: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the kidney cancer drugs market, including the Renal Cell Carcinoma (RCC) market; the disease overview, symptoms, causes, and diagnosis; an overview of the presently available therapeutic classes, including multi-kinase inhibitors, mTOR, and others; the recent product approvals, the pipeline drugs, the key corporate initiatives, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for kidney cancer drugs market for the years 2008 through 2017 for the following geographic markets – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Key therapeutic classes analyzed include Multikinase Inhibitors, and other therapeutics classes.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Kidney_Cancer_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1300 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###





More Carcinoma Press Releases

Read More

New Studies on Breast Carcinoma

October 21, 2011     No comments

According to the American Cancer Society statistics, breast cancer accounts for nearly one in three cancers diagnosed in American women. Breast cancer affects one in eight women during their lives. Breast cancer kills more women in the United States than any cancer except lung cancer. No one knows why some women get cancer, but there are a number of risk factors. The incidence of breast cancer increases dramatically after age fifty, with fifty percent of breast cancers diagnosed in women over the age of forty-five.

Obese women, especially those who are post-menopausal, women who consume excessive amounts of alcohol (greater than two ounces per day) and those who smoke are at increased risk. in addition, there are two genes, BRCA1 and BRCA2 that greatly increase the risk. Another risk factor is a personal one – beginning periods before the age of 12 or going through menopause after the age of 55. Other risks include being overweight, using hormone replacement therapy, taking birth control pills, drinking alcohol, not having children, having your first child after age 35, or having dense breasts.

Men also get breast carcinoma. Each year it is estimated that approximately 1,700 men will be diagnosed with cancer and 450 will die. While this percentage is still small, men should also give themselves regular breast self-exams and note any changes to their physicians.

Every year, scientists and doctors worldwide make researches in order to understand better the risks and the evolution of this type of cancer and to find a cure.

]]>

For instance, a new Canadian study revealed that aspirin and ibuprofen lower the risk of women developing this type of cancer. The study shows that aspirin accounts for 13 percent less breast cancer cases among women using the drug, while ibuprofen decreases the risk of cancer developing by more than 21 percent. However, the Canadian scientists who conducted this study caution women not to start using these drugs as of yet, because they have strong side-effects. ‘The results of this study just show that women who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) for other reasons probably have a lower risk of cancer,’ said Bahi Takkouche, M.D., Ph.D., of the University of Santiago de Compostela in Spain, co-author of the study. In medical tests, NSAIDs have been proven to inhibit the enzyme cyclooxygenase (COX), which scientists believe plays a crucial role in producing inflammatory mediators that favor the development of mutant cells.

Moreover, according to a study published in Breast Cancer Research, regular activity such as running, heavy housework, demanding yard work, aerobics, was found to reduce a woman’s breast carcinoma risk with 30 percent. The study was conducted over an 11-year period and included 32,000 women who were post-menopausal. However, the activity only protected women if they were neither overweight nor obese. Contrary to other studies, that have shown that light activity had an impact on the risk of cancer in the long run, this study shows that light exercise had no effect against cancer.

Furthermore, a recent study has shown that women who suffer from migraines can be at an important lower risk to develop breast carcinoma. Christopher Li, MD, of the Fred Hutchinson Cancer Research Center in Seattle, stated that ‘many of the types of

Read More

Asbestos Exposure and the Increased Risk of Carcinoma

October 21, 2011     No comments

Mesothelioma is a deadly disease that has taken thousands of lives.  The more public awareness that is brought to this disease, the better.  One interesting study is called, “Unsuspected exposure to asbestos and bronchogenic carcinoma” by K M Martischnig, D J Newell, W C Barnsley, W K Cowan, E L Feinmann, E Oliver – Br Med J  1977;1:746-749 (19 March).  Here is an excerpt: “Two hundred and fifty men admitted to a thoracic surgical centre and matched controls were questioned in detail about their occupations after leaving school and their smoking habits. Of 201 men with confirmed bronchial carcinoma 58 gave a history of occupational exposure to asbestos, whereas only 29 out of 201 men matched for age and residential area who were admitted with other diseases gave such a history. This difference was statistically highly significant. The usual association of bronchial carcinoma with heavy smoking was observed, but asbestos exposure increased the risk of carcinoma whatever the level of smoking. These results are consistent with the hypothesis that asbestos exposure and the level of smoking act independently in causing bronchial carcinoma. The patients with carcinoma who had been exposed to asbestos presented on average three years earlier than those who had not been exposed. Asbestos regulations have eliminated the risk of exposure to workers in scheduled industries, so asbestos-induced diseases will probably be increasingly found among the many workers who have had incidental exposure to asbestos. It is therefore important to take a full occupational history.”

Another interesting study is called, “Asbestos and mesothelioma: Worldwide trends” by Laurie Kazan-Allen – Volume 49, Supplement 1, Pages S3-S8 (July 2005).  Here is an excerpt: “Summary – A correlation between national asbestos consumption and the incidence of asbestos disease, including mesothelioma, has been observed. Towards the end of the 20th century, governments in many developed countries banned or seriously restricted the use of asbestos. As a result, global asbestos producers have engaged in aggressive marketing campaigns to sell asbestos to developing countries; consumption of white asbestos is increasing in Asia, Latin America and the Commonwealth of Independent States. In most of the countries, there is little, if any, control on hazardous asbestos exposures from occupational, environmental and domestic sources. It is likely that the lethal asbestos harvest which is occurring in the U.S., the UK and Australia will be reproduced in the developing world.”

A third study worth examining is called, “Response of mouse lung to crocidolite asbestos, Minimal fibrotic reaction to short fibres” by Dr Ian Y. R. Adamson, Drummond H. Bowden – Department of Pathology, University of Manitoba, Winnipeg, Canada – The Journal of Pathology Volume 152 Issue 2, Pages 99 – 107.  Here is an excerpt: “Abstract – To determine the relationship between the development of pulmonary fibrosis and the size of deposited asbestos, we prepared a pure sample of short crocidolite fibres and instilled 0.5 mg of 0.1 mg to the lungs of mice. Animals were killed up to 20 weeks later with 3H thymidine injected 1 h before death. By bronchoalveolar lavage, there was a rapid transient increase in polymorph neutrophils (PMN) and in glucosaminidase levels; alveolar macrophage (AM) numbers were elevated in the 0.5 mg group for eight weeks. Most fibres were

Read More

What is Squamous Cell Skin Carcinoma Skin Cancer?

October 19, 2011     No comments

A squamous cell carcinoma skin cancer is a type of skin cancer that usually results from a long term sun damage or exposure to ultra-violet rays to the skin. Squamous cell carcinoma skin cancer spreads gradually and also has the capacity to spread to tissues near the affected area such as the eye. The cancer can also spread to distant parts of the body in case, it is not treated on time.

The best and the only way to make sure if a skin growth is cancerous is to go for a biopsy. The process involves removal of a small section of the skin. Thereafter a pathologist analyzes it under the microscope in a medical laboratory.

Remember that a biopsy is not a process to remove cancer. It just works towards taking off the tip of the cancer.

In some cases the skin tends to heal once the biopsy is done as it grows over the cancer. However, this does not indicate that the cancer is removed completely. Here, the cancer is only covered with a blanket of skin. In case, the cancer is not removed fully, it can get deeper in to the skin and even metastasize to the internal organs of the body resulting in death of a human being.

]]>

Squamous cell carcinoma skin cancer is known to be one of the most common forms of skin cancer. It is shocking but true that over 25,000 new cases have been reported in a year in the United States alone. The cancer originates from the squamous cells that are most of the portion of the upper layer of the skin.

All cases of squamous cell carcinoma skin cancer are not serious. If detected early and treated promptly, one can easily survive this disease. However, if not treated properly, the disease can prove to be very hard to treat and can even result in disfigurement.

There are several causes of the origination of squamous cell carcinoma skin cancer. Some of these include the following:

i) Frequent and long exposure to harmful sun rays. This result in severe skin damage and ultimately develop in to squamous cell carcinoma skin cancer.

ii) The damage to the skin done by sun is the most responsible factor for development of this type of cancer. The face is most exposed to sun and the cancer spreads to the other parts of the body.

iii) Light skinned people have greater risk of developing squamous cell carcinoma skin cancer.

iv) People who have already developed this cancer are said to develop more.

Chronic exposure to the sun is the main cause of this type of cancer. The tumor invades to body parts such as face, neck, bald scalp, hands, shoulders, arms and back that are more exposed to sun. The lower lip and the rim of the ear are more vulnerable to these cancers.

Squamous cell carcinoma skin cancer may also develop due to certain types of injury such as scars, burns, long existing sores, sites exposed to X-rays or some harmful chemicals, such as arsenic of by-products of petroleum. Reduced immunity is also one of the main reasons for the spread of this type of cancer. Detect and treat early to stay away from possible damage and full recovery.

For more Articles, News, Information, Advice, and Resources about SKIN CANCER please visit SKIN CANCER REPORT

Read More
« Older posts
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv